Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology and Market Forecast to 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Idiopathic
Pulmonary Fibrosis (IPF) – Market Insights, Epidemiology and Market
Forecast-2027”
report has been added to ResearchAndMarkets.com’s
offering.

Idiopathic Pulmonary Fibrosis (IPF) – Market Insights, Epidemiology and
Market Forecast-2027′ report delivers an in-depth understanding of the
disease, historical & forecasted epidemiology as well as the market
trends of IPF in the United States, EU5 (Germany, Spain, Italy, France
and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs
having the potential to get launched in the forecast period, market
share of the individual therapies, current and forecasted market size of
Idiopathic Pulmonary Fibrosis (IPF) from 2016 to 2027 segmented by seven
major markets. The Report also covers current treatment
practice/algorithm, market drivers, market barriers and unmet medical
needs to curate best of the opportunities and assess underlying
potential of the market.

Key Topics Covered:

1. Key Insights

2. IPF Market Overview at a Glance

2.1. Market Share (%) Distribution of IPF in 2017

2.2. Market Share (%) Distribution of IPF in 2027

3. Disease Background and Overview: Idiopathic Pulmonary
Fibrosis (IPF)

3.1. Introduction

3.2. Staging of IPF

3.3. Risk Factors & Disease Causes

3.4. Symptoms

3.5. Pathogenesis

3.6. Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7 MM Prevalent Population of IPF

4.3. Country Wise-Epidemiology of IPF

5. Current Treatment Practices

5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An
Update of 2011 Clinical Practice Guideline)

6. Unmet needs

7. Marketed Products

7.1. Esbriet (Pirfenidone): InterMune Inc.

7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG

8. Emerging Therapies

9. Key Cross Competition

10. Phase III Drugs

10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation

11. Phase II Drugs

11.1. CC-90001: Celgene Corporation

11.2. Gefapixant: Merck & Co., Inc.

11.3. GLPG1690: Galapagos NV

11.4. LT-1001: LTT Bio-Pharma

11.5. BG00011: Biogen Inc.

11.6. BMS-986020: Bristol-Myers Squibb

11.7. LT-1002: Chong Kun Dang Pharmaceutical

11.8. Pamrevlumab: FibroGen

11.9. PBI4050: ProMetic Life Sciences

11.10. PRM 151: Promedior, Inc.

11.11. Tipelukast: MediciNova

11.12. TD139: Bristol-Myers Squibb

11.13. VAY736: Novartis

11.14. TAS-115: Taiho Pharmaceutical

12. IPF: Market Analysis

12.1. Key Findings

12.2. Total Market Size of IPF in 7 MM

12.3. Therapy Based Market Size of IPF in 7 MM

13. Market Size of IPF by Country

14. Market Drivers of IPF

15. Market Barriers of IPF

16. Appendix

16.1. Report Methodology

17. Capabilities

For more information about this report visit https://www.researchandmarkets.com/research/slfg3c/idiopathic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs